Coagulation point-of-care testing on the labour ward should be mandatory

International Journal of Obstetric Anesthesia

Volumn 27, Issue , 2016, Pages 66-69

  Collis, R ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA;

ARTICLE; BLOOD COMPONENT THERAPY; BLOOD GLUCOSE MONITORING; BLOOD SUBSTITUTION; FEMALE; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; POSTPARTUM HEMORRHAGE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOELASTOGRAPH; URINALYSIS; BLOOD CLOTTING TEST; LABOR; PREGNANCY;

BLOOD COAGULATION TESTS; FEMALE; HUMANS; LABOR, OBSTETRIC; PARTIAL THROMBOPLASTIN TIME; POINT-OF-CARE TESTING; POSTPARTUM HEMORRHAGE; PREGNANCY;

EID: 84990982125     PISSN: 0959289X     EISSN: 15323374     Source Type: Journal    
DOI: 10.1016/j.ijoa.2016.06.006     Document Type: Article

References (22)

1. 1 Royal College of Obstetricians and Gynaecologists Green top Green-top Guideline no. 52 Prevention and management of postpartum haemorrhage. May 2009 Minor revisions November 2009 and April 2011. www.rcog.org.uk/globalassets/documents/guidelines/gt52postpartumhaemorrhage0411.pdf [accessed June 2016].
2. 2 National Institute for Health and Care Excellence Guidance. https://www.nice.org.uk/donotdo/only-consider-fresh-frozen-plasma-transfusion-for-patients-with-clinically-significant-bleeding-but-without-major-haemorrhage-if-they-have-abnormal-coagulation-test-results-for-example-prothrombin-time-ratio-or-activated-partial-thromboplastin-time-ratio- [accessed June 2016].
3. 3 Hunt, B.J., Allard, S., Keeling, D., Norfolk, D., Stanworth, S.J., Pendry, K., British Committee for Standards in Haematology. A practical guideline for the haematological management of major haemorrhage. Br J Haematol 170 (2015), 788–803.
4. 4 Paterson-Brown, S., Bamber, J., on behalf of the MBRRACE-UK haemorrhage chapter writing group. Prevention and treatment of haemorrhage. Kenyon, S., Brocklehurst, P., Neilson, J., Shakespeare, J., Kurinczuk, J.J., Knight, M., (eds.) on behalf of MBRRACE-UK. Saving Lives, Improving Mothers’ Care – Lessons learned to inform future maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity. 2009–12, 2014, National Perinatal Epidemiology Unit, University of Oxford, Oxford, 45–55.
5. 5 Lennox C, Marr L. Scottish Confidential Audit of Severe Maternal Morbidity: reducing avoidable harm 10th Annual report. www.healthcareimprovementscotland.org/our_work/reproductive,_maternal_child/programme_resources/scasmm.aspx [accessed June 2016].
6. 6 Hildyard, C., Curry, N., Point-of-care testing: a standard of care?. Anaesthesia 70 (2015), 1113–1118.
7. 7 Solomon, C., Collis, R.E., Collins, P.W., Erythrocytes, haemostasis, and coagulation monitoring in postpartum haemorrhage (PPH). Br J Anaesth 110 (2013), 1054–1055.
8. 8 Huissoud, C., Carrabin, N., Audibert, F., et al. Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. BJOG 116 (2009), 1097–1102.
9. 9 Collins, P.W., Lilley, G., Bruynseels, D., et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood 124 (2014), 1727–1736.
10. 10 Whiting, P., Al, M., Westwood, M., et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess 19 (2015), 1–228 v–vi.
11. 11 Detecting, managing and monitoring haemostasis: viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems). NICE diagnostics guidance [DG13] August 2014. www.nice.org.uk/guidance/dg13/chapter/1-recommendations [accessed June 2016].
12. 12 Afshari, A., Wikkelsø, A., Brok, J., Møller, A.M., Wetterslev, J., Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev, 3, 2011 Mar 16, CD007871.
13. 13 Collins, P.W., Solomon, C., Sutor, K., et al. Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. Br J Anaesth 113 (2014), 585–595.
14. 14 de Lloyd, L., Bovington, R., Kaye, A., et al. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth 20 (2011), 135–141.
15. 15 Charbit, B., Mandelbrot, L., Samain, E., et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 5 (2007), 266–273.
16. 16 Mallaiah, S., Barclay, P., Harrod, I., Chevannes, C., Bhalla, A., Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia 70 (2015), 166–175.
17. 17 Mallaiah, S., Chevannes, C., McNamara, H., Barclay, P., A reply. Anaesthesia 70 (2015), 760–761.
18. 18 Wikkelsø, A.J., Edwards, H.M., Afshari, A., et al. FIB-PPH trial group. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth 114 (2015), 623–633.
19. 19 Bruynseels, D., Dick, J., Elton, C.D., Mallaiah, S., Collis, R.E., on behalf of OBS2 collaboration. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: a multicentre, prospective, double-blind randomised control study (OBS2). Int J Obstet Anesth, 26, 2016, S6.
20. 20 Moses, T., Leslie, D., Bell, S.F., Collis, R.E., The effects of audit and research in postpartum haemorrhage: benefits for all!. Int J Obstet Anesth, 26, 2016, S15.
21. 21 Aawar, N., Alikhan, R., Bruynseels, D., et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomised controlled trial. Trials, 16, 2015, 169.
22. 22 Collis, R.E., Collins, P.W., Haemostatic management of obstetric haemorrhage. Anaesthesia. 70:Suppl 1 (2015), 78–86 e27–8.